DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector, specifically in the Medical - Care Facilities industry. The company is a leading U.S. provider of kidney dialysis services and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, it ran 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients, plus 585 international outpatient dialysis centers across 14 countries serving roughly 94,500 patients. Its care model spans outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, kidney transplantation support, integrated kidney care, and ancillary services.

The financial footprint is distinctive. DaVita reports a net margin of 6.0%, which is solid but not exceptionally wide for a healthcare services business with heavy fixed assets and labor intensity. More striking is the return on equity of -123.6%. A negative ROE of this magnitude typically signals that shareholders' equity is negative—often the result of accumulated share buybacks, debt-funded operations, or accounting losses rather than a pure operating problem. In DaVita's case, the dialysis industry is capital-light per treatment but balance-sheet-heavy once leases, clinic debt, and acquisition history are layered in. The negative equity means ROE is not a useful standalone profitability compass here; investors usually substitute metrics like return on invested capital or EBITDA margins. The 6.0% net margin, combined with the company's scale and its long-standing leadership in CMS quality programs, points to a business with durable volume and payer relationships, but not one that enjoys a wide, unassailable economic moat purely on margin.

Financial posture

DaVita's current market capitalization stands at $11.6 billion, with the stock trading at $180.97. The P/E ratio is 15.6, below the premium valuations often seen in faster-growing healthcare services names but in line with a mature, regulated services provider. The beta is 0.83, indicating lower volatility than the broader market and a defensive posture typical of non-discretionary healthcare services.

The financial posture is best understood as stable but highly leveraged in capital-structure terms. The negative ROE of -123.6% is the loudest signal: the equity base is thin or negative, while the operating business continues to generate cash. The 6.0% net margin is the counterweight—it shows the core dialysis service is profitable at the bottom line. For analysis, the usual P/E and ROE pairing is distorted; practitioners tend to focus on enterprise value multiples, cash-flow coverage, and net-debt trends rather than the equity denominator. The current share dynamics also reflect this tension: the stock is below its 50-day EMA of $189.60, with an RSI of 46.1, suggesting neither overbought nor oversold conditions.

Strategic priorities & outlook

In its most recent 10-K filing, DaVita laid out three operational themes that define its near-term strategy. First, it wants to reimagine kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities that coordinate treatment across the full renal continuum—from chronic kidney disease to end-stage kidney disease to kidney transplant. Third, the company is supporting the goals of the Comprehensive Kidney Care Contracting model, which aims to delay disease progression, promote home dialysis when clinically appropriate, and incentivize transplants.

Two quantitative facts from the filing frame the revenue and risk profile. U.S. dialysis revenues represented approximately 86% of consolidated revenues, and nearly all non-hospital dialysis profits came from commercial payors. That concentration means profitability is highly sensitive to commercial reimbursement rates and mix, even though the majority of treatments are funded by government payors. On the quality side, DaVita has been an industry leader in CMS's Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years, which can influence referral patterns and reimbursement bonuses.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita is primarily exposed to U.S. healthcare policy, Medicare reimbursement rules, and Medicaid funding at the state level. Dialysis is uniquely concentrated in government reimbursement: Medicare covers most end-stage kidney disease patients regardless of age. Any change to the Medicare physician fee schedule, the End-Stage Renal Disease prospective payment system, or the Comprehensive Kidney Care Contracting model directly affects revenue and margins.

Because the business is service-based and domestic-revenue-heavy, it has limited direct commodity-price exposure and modest currency sensitivity outside its 14-country international footprint. The main macro risks are regulatory—reimbursement cuts, quality-program penalties, and changes to commercial insurance regulation—and labor-cost inflation at the clinic level, since dialysis centers depend on nurses, technicians, and social workers. Trade policy and supply-chain disruptions are secondary concerns compared with reimbursement and labor, though any tariff or shortage affecting dialysis machines and consumables could matter at the margin.

Recent developments

Recent news coverage has been mixed and price-focused. On September 24, 2026, Zacks published "DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note," flagging a period of underperformance. A week earlier, on September 16, 2026, Zacks ran the opposite headline: "DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors," noting relative strength. The same day, Benzinga listed DaVita among "Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You," a novelty angle that highlights ownership overlap but does not carry operational implications. On September 21, 2026, MarketBeat included DaVita in "3 Surging Stocks That Don't Need the AI Boom to Keep Winning," framing it as a non-technology momentum name. Together these headlines underscore a stock that has been volatile and news-sensitive rather than one with a clean directional narrative.

Earnings behavior & post-earnings drift

DaVita has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 2.3%. Across those quarters, the average 5-day price move after earnings has been 6.36% to the upside, classified as upward post-earnings drift.

Yet the last four quarters illustrate why headline beat-rate statistics can mislead. The most recent report, on August 4, 2026, was a clear beat: actual EPS of $4.02 against an estimate of $3.88, a 3.6% positive surprise. The stock fell 17.24% the next day and 21.78% over the following five days. In contrast, the May 5, 2026 report delivered a $2.87 actual EPS against a $2.41 estimate, a 19.1% surprise, and the stock rose 23.46% the next day and 27.7% over five days. The February 2, 2026 quarter was a $3.40 actual versus $3.24 estimate, a 4.9% beat, producing a 21.17% one-day gain and 23.79% five-day gain. The October 29, 5 miss—$2.51 actual versus $3.17 estimate, a -20.8% surprise—brought a -6.17% next-day drop and -4.27% five-day decline.

The notable pattern is that beats do not automatically produce continued upward drift, and misses are not always the worst performers. The August 2026 beat produced the largest five-day decline, suggesting the market realign itself with forward guidance, payer mix commentary, or policy fears rather than the quarterly EPS print alone. This is the real disconnect for traders: the unofficial consensus may be captured by the EPS estimate, but the post-earnings move depends on what management says about commercial reimbursement, patient growth, and Medicare policy. The next scheduled report is November 4, 2026, after the close, with the consensus EPS estimate at $3.55.

For a deeper dive into how institutional analysts view DaVita's valuation, margin trajectory, and reimbursement risk ahead of the November 4 report, see the full institutional verdict on the platform.